Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.53 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.48 |
| ▸ | RBP4 | P02753 | 3/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.44 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | LIPE | Q05469 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21381979 | 0.89 | GPR119 (0.49) | CHRNA7SCN9AGPR119RORCTACR1 | |
| SCHEMBL21723071 | 0.88 | RBP4 (0.49) | RBP4GPR119 | |
| SCHEMBL23850247 | 0.86 | GPR119 (0.49) | CHRNA7SCN9AGPR119RORCTACR1 | |
| SCHEMBL20893623 | 0.85 | USP30 (0.54) | CHRNA7SCN9ARBP4GPR119ALOX5AP | |
| SCHEMBL22462872 | 0.83 | IDO1 (0.41) | GPR119RORCTACR1MAPTNAMPT | |
| SCHEMBL21723050 | 0.80 | MGLL (0.51) | GPR119RORCTACR1MAPTNAMPT | |
| SCHEMBL23091766 | 0.79 | GPR119 (0.48) | GPR119RORCTACR1MAPTLIPE | |
| SCHEMBL23211881 | 0.79 | RORC (0.42) | GPR119RORCTACR1MAPT | |
| SCHEMBL31330761 | 0.79 | RBP4 (0.58) | CHRNA7SCN9ARBP4GPR119ALOX5AP | |
| SCHEMBL30013316 | 0.79 | GPR119 (0.48) | GPR119RORCTACR1MAPTLIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| EP-4469446-A1 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023144160-A1 | NEW HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-03 | — | — | WO | disclosed |
| EP-3279191-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-09-02 | — | — | EP | disclosed |
| US-10106556-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-23 | — | — | US | disclosed |
| US-20180079756-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-22 | — | — | US | disclosed |
| EP-3279191-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079756-A1 | HETEROCYCLIC COMPOUND | MAG, ACHE, HTT | CHRNA7 429/4885SCN9A 518/4885RBP4 4756/4885 |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | CHRNA7 703/4885SCN9A 1164/4885RBP4 3779/4885 |
| US-10106556-B2 | Heterocyclic compound | MAG, ACHE, HTT | CHRNA7 429/4885SCN9A 518/4885RBP4 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.